Astellas Pharma Inc.
Mitsubishi Tanabe Pharma Corporation

Astellas and Mitsubishi Tanabe Pharma Execute Agreement
for Share of Compound Libraries
Tokyo and Osaka, March 29, 2016 - Astellas Pharma Inc. (President and CEO: YoshihikoHatanaka, “Astellas”) and Mitsubishi Tanabe Pharma Corporation (President andRepresentative Director: Masayuki Mitsuka, “Mitsubishi Tanabe Pharma”) today announced
that the companies concluded an agreement for the share of their respective approximately
250,000 compounds selected from their respective compound libraries, including a significant
number of proprietary synthetic compounds. This alliance enables each company to further
accelerate drug discovery research of innovative new drugs.
This alliance allows each company to access qualitatively different and original compound
library held by the other company - which have been aggregated respectively based on eachcompany’s independent research strategy - allowing both companies to implement broader
High Throughput Screening (HTS)1) to increase opportunities to discover compounds which
will reach to new drug seeds.
For a period of five years from April 1, 2016, this alliance will enable each company to freely
implement broad HTS using the compounds received from the other company. In line with thisalliance, each company will disclose sufficient information to enable the other company toimplement HTS independently.
If one of the companies identifies a lead compound, that company will have a right to further
research, develop and commercialize such compound without any restriction of the indicationsuch as human diseases and diagnosis pursuant to the terms of agreement.
Through this alliance, Astellas and Mitsubishi Tanabe Pharma aim to effectively utilize bothparties’ assets and knowledge and accelerate open innovation while taking advantage of theirown strengths to place innovative new drugs on the market.

11)

A method of high-speed screening of molecules that respond to potential drug targets from an

extremely large number of compounds, through an automation. HTS plays an important role inearly drug discovery and is an effective technique for finding good candidate compounds that leadto new drugs.
About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health ofpeople around the world through the provision of innovative and reliable pharmaceutical products.
We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritizedtherapeutic areas while advancing new therapeutic areas and discovery research leveraging newtechnologies/modalities. We are also creating new value by combining internal capabilities andexternal expertise in the medical/healthcare business. Astellas is on the forefront of healthcarechange to turn innovative science into value for patients. For more information, please visit ourwebsite at www.astellas.com/en.
About Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma Corporation is a research-driven pharmaceutical company of which
Head Office based in Dosho-machi Osaka where the birthplace of Japan’s pharmaceutical industry.
Based on our philosophy “We contribute to the healthier lives of people around the world throughthe creation of pharmaceuticals”, we formulated the “Medium-Term Management Plan 16-20: OpenUp the Future.” We are taking on the challenge of drug discovery that address unmet medical needsin the fields of priority disease areas; “autoimmune disorders,” “diabetes and kidney diseases,”“central nervous system diseases” and “vaccines.” To those ends, we contribute to the healthier livesof people around the world. http://www.mt-pharma.co.jp/eContacts:
Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201

FAX:+81-3-5201-7473

http://www.astellas.com/en
Mitsubishi Tanabe Pharma Corporation
Corporate Communications Deapartment
TEL: +81-6-6205-5211

FAX: +81-6-6205-5105

http://www.mt-pharma.co.jp/e###2